59.95
+0.54(+0.91%)
Currency In USD
| Previous Close | 59.41 |
| Open | 59.24 |
| Day High | 60.14 |
| Day Low | 58.49 |
| 52-Week High | 68.58 |
| 52-Week Low | 35.17 |
| Volume | 385,258 |
| Average Volume | 605,093 |
| Market Cap | 3.68B |
| PE | -13.88 |
| EPS | -4.32 |
| Moving Average 50 Days | 57.67 |
| Moving Average 200 Days | 49.14 |
| Change | 0.54 |
If you invested $1000 in Rhythm Pharmaceuticals, Inc. (RYTM) since IPO date, it would be worth $2,439.97 as of February 05, 2025 at a share price of $59.95. Whereas If you bought $1000 worth of Rhythm Pharmaceuticals, Inc. (RYTM) shares 5 years ago, it would be worth $3,345.42 as of February 05, 2025 at a share price of $59.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones
GlobeNewswire Inc.
Jan 10, 2025 12:15 PM GMT
-- Preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) of approximately $42 million for the fourth quarter of 2024 and approximately $130 million for the full year of 2024 -- -- On track to report topline data from glob
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old
GlobeNewswire Inc.
Dec 20, 2024 7:15 PM GMT
BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S
Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old
GlobeNewswire Inc.
Dec 03, 2024 11:00 AM GMT
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that